234 related articles for article (PubMed ID: 19395457)
1. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus.
Pena-Rossi C; Nasonov E; Stanislav M; Yakusevich V; Ershova O; Lomareva N; Saunders H; Hill J; Nestorov I
Lupus; 2009 May; 18(6):547-55. PubMed ID: 19395457
[TBL] [Abstract][Full Text] [Related]
2. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
Dall'Era M; Chakravarty E; Wallace D; Genovese M; Weisman M; Kavanaugh A; Kalunian K; Dhar P; Vincent E; Pena-Rossi C; Wofsy D
Arthritis Rheum; 2007 Dec; 56(12):4142-50. PubMed ID: 18050206
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus.
Nestorov I; Papasouliotis O; Pena Rossi C; Munafo A
J Pharm Sci; 2010 Jan; 99(1):524-38. PubMed ID: 19743503
[TBL] [Abstract][Full Text] [Related]
4. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.
Tak PP; Thurlings RM; Rossier C; Nestorov I; Dimic A; Mircetic V; Rischmueller M; Nasonov E; Shmidt E; Emery P; Munafo A
Arthritis Rheum; 2008 Jan; 58(1):61-72. PubMed ID: 18163485
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).
Isenberg D; Gordon C; Licu D; Copt S; Rossi CP; Wofsy D
Ann Rheum Dis; 2015 Nov; 74(11):2006-15. PubMed ID: 24951103
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
Munafo A; Priestley A; Nestorov I; Visich J; Rogge M
Eur J Clin Pharmacol; 2007 Jul; 63(7):647-56. PubMed ID: 17473917
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis.
Nestorov I; Munafo A; Papasouliotis O; Visich J
J Clin Pharmacol; 2008 Apr; 48(4):406-17. PubMed ID: 18303125
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
[TBL] [Abstract][Full Text] [Related]
10. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
Stohl W; Merrill JT; Looney RJ; Buyon J; Wallace DJ; Weisman MH; Ginzler EM; Cooke B; Holloway D; Kaliyaperumal A; Kuchimanchi KR; Cheah TC; Rasmussen E; Ferbas J; Belouski SS; Tsuji W; Zack DJ
Arthritis Res Ther; 2015 Aug; 17(1):215. PubMed ID: 26290435
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.
Merrill JT; Wallace DJ; Wax S; Kao A; Fraser PA; Chang P; Isenberg D;
Arthritis Rheumatol; 2018 Feb; 70(2):266-276. PubMed ID: 29073347
[TBL] [Abstract][Full Text] [Related]
12. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept.
Carbonatto M; Yu P; Bertolino M; Vigna E; Steidler S; Fava L; Daghero C; Roattino B; Onidi M; Ardizzone M; Peano S; Visich J; Janszen D; Dillon S; Ponce R
Toxicol Sci; 2008 Sep; 105(1):200-10. PubMed ID: 18522929
[TBL] [Abstract][Full Text] [Related]
13. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
14. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.
Morand EF; Isenberg DA; Wallace DJ; Kao AH; Vazquez-Mateo C; Chang P; Pudota K; Aranow C; Merrill JT
Rheumatology (Oxford); 2020 Oct; 59(10):2930-2938. PubMed ID: 32107560
[TBL] [Abstract][Full Text] [Related]
15. [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].
Hartung HP
Nervenarzt; 2009 Dec; 80(12):1462-72. PubMed ID: 19779889
[TBL] [Abstract][Full Text] [Related]
16. Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus.
Wallace DJ; Isenberg DA; Morand EF; Vazquez-Mateo C; Kao AH; Aydemir A; Pudota K; Ona V; Aranow C; Merrill JT
Rheumatology (Oxford); 2021 Nov; 60(11):5379-5389. PubMed ID: 33547784
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus.
Zhao Q; Chen X; Hou Y; Jiang J; Zhong W; Yao X; Wang W; Li L; Fang J; Zhang F; Hu P
J Clin Pharmacol; 2016 Aug; 56(8):948-59. PubMed ID: 26634642
[TBL] [Abstract][Full Text] [Related]
18. Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.
Gordon C; Wofsy D; Wax S; Li Y; Pena Rossi C; Isenberg D
Arthritis Rheumatol; 2017 Jan; 69(1):122-130. PubMed ID: 27390168
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma.
Ansell SM; Witzig TE; Inwards DJ; Porrata LF; Ythier A; Ferrande L; Nestorov I; Devries T; Dillon SR; Hausman D; Novak AJ
Clin Cancer Res; 2008 Feb; 14(4):1105-10. PubMed ID: 18281543
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
